Market Intelligence, Clinical Progress, and High-Purity Reagents for Mucosal Immunity and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PIGR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PIGR ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PIGR Products |
| Gene Delivery | PIGR Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PIGR Products |
| Benchmark Ab | Anti-PIGR Recombinant Antibody Recombinant positive control. |
View PIGR Products |
| Validator | PIGR siRNA Set For knockdown verification. |
View PIGR Products |
| Related Target A | IGJ Immunoglobulin J chain, essential for dimeric IgA assembly and PIGR binding. |
View IGJ Products |
| Related Target B | FCAMR Fc alpha/mu receptor, co-mediator of mucosal IgA/IgM responses. |
View FCAMR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| In vitro transcytosis modeling | Lentivirus premade particles for stable expression in MDCK/Caco-2 cells |
| Native conformational binding | HEK293 expressed PIGR extracellular domain (ECD) with native glycosylation |
| Lack of positive controls | Sequence-verified clinical benchmark antibodies available |
| Specificity & knockdown validation | Sequence-verified siRNA sets for target validation |
Live PIGR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The polymeric immunoglobulin receptor (PIGR) is a key transmembrane glycoprotein mediating the transcytosis of polymeric IgA and IgM across mucosal epithelial cells. The race for PIGR therapeutics is intensifying, with major players shifting focus from traditional mAbs to mucosal drug delivery vehicles and oncology therapeutics. As first-generation therapies reach the clinic, the next wave of R&D is targeting PIGR-mediated transcytosis for non-invasive drug delivery and targeting PIGR-positive mucosal tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Mucosal Delivery Conjugates | Academic Institutes, Biotech Startups | Respiratory Infections, IBD | Transcytosis Assay (Need Lentivirus for Stable Cell Lines) |
| Monoclonal Antibodies | Biopharma Corporates | Mucosal Carcinomas, Immunotherapy | Affinity & Epitope Mapping (Need HEK293 Expressed ECD-Fc) |
| Bispecific / IgA Platforms | IgA-focused Biotechs | Infectious Diseases, Oncology | Heterodimer Validation (Need High-Purity IGJ and PIGR Proteins) |